WishBone Medical, Inc. and Hospital for Special Surgery (HSS) Collaborate to Develop a Novel Pediatric Total Hip Implant.

NEW YORK, March 07, 2018 -- WishBone Medical, Inc., a new global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants, entered into a license agreement with the global leader in orthopedic surgery, Hospital for Special Surgery (HSS), for the development of a novel Pediatric Total Hip. The system will be developed to address treatment of juvenile idiopathic arthritis (JIA) patients or young patients with congenital dysplastic hip (CDH) disease.

“We look forward to working with HSS on a Pediatric Total Hip system designed just for kids,” said Nick Deeter, Chairman of the Board and CEO at WishBone Medical. “HSS is the premier musculoskeletal hospital in the world and their expertise and collaboration will be invaluable to develop this technology.”

“HSS’s clinical leadership, biomechanical engineering and innovation expertise together with Wishbone’s experience developing technologies to serve pediatric patients, position us to improve the quality of life of these young patients who do not have many therapeutic options,” said Louis A. Shapiro, president and CEO of HSS. “As an inventor of these technologies, Dr. Mark Figgie, our Chief of the Surgical Arthritis Service at HSS is a leading expert in the field, who along with our biomechanical engineers have a long history in both treating and innovating for this patient population,” Shapiro added.

About WishBone Medical, Inc.

WishBone Medical is a Global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing. To learn more about WishBone Medical, visit www.WishBoneMedical.com 

For more information, please call Andrew Miclot, Vice-Chairman and President at 574-306-4006 or email [email protected].

About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the eighth consecutive year) and No. 3 in rheumatology by U.S. News & World Report (2017-2018). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients from 80 countries and performed more than 32,000 surgical procedures. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute was formed in 2015 to realize the potential of new drugs, therapeutics and devices; the global standard total knee replacement was developed at HSS in 1969, and in 2017 HSS made 130 invention submissions (more than 2x the submissions in 2015). The HSS Education Institute provides continuing medical curriculum to more than 15,000 subscribing musculoskeletal healthcare professionals in 110 countries. Through HSS Global, the institution is collaborating with medical centers worldwide to advance the quality and value of care and to make world-class HSS care more accessible to more people.